Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs)

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Prostate cancer (PCa) is the second most common cancer in men globally.
• Genomic alterations, including copy number changes and gene rearrangements (e.g., ERG, MYC, TP53, PTEN), are hallmarks of PCa.
• Understanding these alterations is crucial for advancing PCa research.

Purpose of the Study:

• To review the primary genes altered in prostate cancer.
• To discuss how genetically engineered mouse models (GEMMs) represent these key genomic alterations.
• To explore the utility of GEMMs in studying PCa molecular mechanisms.

Main Methods:

• Review of existing literature on PCa genomics.
• Analysis of genetically engineered mouse models (GEMMs) relevant to PCa.
• Focus on modeling key oncogenes and tumor suppressor genes.

Main Results:

• Identification of frequently altered genes in PCa, including oncogenes (ERG, MYC) and tumor suppressor genes (TP53, PTEN).
• Demonstration of various GEMMs that recapitulate specific genomic alterations found in human PCa.
• Highlighting the role of GEMMs in dissecting molecular pathways of PCa development.

Conclusions:

• Genetically engineered mouse models are essential tools for studying prostate cancer genomics.
• GEMMs facilitate the investigation of molecular mechanisms driving PCa initiation and progression.
• This review synthesizes current knowledge on PCa-associated gene alterations and their modeling.